Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 3Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Recruiting 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Thrombosis 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Disease 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thrombophilia 1Thrombocytopenia 1Thoracic Neoplasms 1Skin Neoplasms 1Pituitary Neoplasms 1Pediatric Solid Tumor, Unspecified, Protocol Specific 1Papillomavirus Infections 1

Interventions

Paclitaxel 23Carboplatin 22Capecitabine 18Gemcitabine 16130-nm albumin-bound paclitaxel 16pembrolizumab 14Cyclophosphamide 12atezolizumab 9Epirubicin 9sacituzumab govitecan 8Albumin-Bound Paclitaxel 8eribulin 6Vinorelbine 6Drug Therapy 6Doxorubicin 6camrelizumab 4Docetaxel 4Cisplatin 4Injections 3pegfilgrastim 2olaparib 2famitinib 2Filgrastim 2Everolimus 2veliparib 1trilaciclib 1toripalimab 1taxane 1niraparib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Triple Negative Breast Neoplasms × Injections × Clear all
NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3 Recruiting
364 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
400 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
332 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡